AbCellera: Why I Do Not Love This Drug Originator’s Organization Design (NASDAQ: ABCL)

Computer code with function error text displayed on pixelated screen with colorful words on dark background

deberarr/iStock through Getty Images

AbCellera ( NASDAQ: ABCL) noted on the Nasdaq in December 2020, finishing a monstrous going public of 24.15 m shares at a cost of $20 per share, for funds of ~$ 483m, which would be directed towards the discovery of antibody


AbCellera partnered program portfolio (AbCellera Discussion)


downstream involvement (AbCellera 10-K )


AbCellera – particles in center (AbCellera discussion)

Like this post? Please share to your friends:
Leave a Reply

;-) :| :x :twisted: :smile: :shock: :sad: :roll: :razz: :oops: :o :mrgreen: :lol: :idea: :grin: :evil: :cry: :cool: :arrow: :???: :?: :!: